Abstract
The goal of clinical research of new disease treatments is to evaluate the potential benefits/risks of a new treatment, which generally requires comparisons to a control group. The control group is selected to characterize what would have happened to a patient if they had not received the new therapy. Although a randomized controlled trial provides the most robust clinical evidence of treatment effects, there may be situations where such a trial is not feasible or ethical, and the use of external or historical controls can provide the needed clinical evidence for granting conditional or accelerated regulatory approvals for novel drugs. Data from previous clinical trials and real-world clinical studies can provide evidence of the outcomes for patients with the disease of interest. However, many methodologic considerations must be considered such as the appropriateness of data sources, the specific data that needs to be collected, application of appropriate inclusion/exclusion criteria, accounting for bias, and statistical adjustment for confounding. This chapter reviews the settings in which the use of historical controls or comparators may be appropriate, as well as study designs, limitations to using real-world comparators, and analytic methods to compare real-world data to clinical trial data. When these considerations are appropriately handled, use of historical controls can have immense value by providing further evidence of the efficacy, effectiveness, and safety in the development of novel therapies and increase efficiency of the conduct of clinical trials and regulatory approvals.
References
D’Agostino RB Jr (1998) Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17:2265–2281
Davies J et al (2018) Comparative effectiveness from a single-arm trial and real-world data: alectinib versus ceritinib. J Comp Eff Res. https://doi.org/10.2217/cer-2018-0032
Desai JR, Bowen EA, Danielson MM, Allam RR, Cantor MN (2013) Creation and implementation of a historical controls database from randomized clinical trials. J Am Med Inform Assoc 20:e162–e168. https://doi.org/10.1136/amiajnl-2012-001257
Dreyer NA (2018) Advancing a framework for regulatory use of real-world evidence: when real is reliable. Ther Innov Regul Sci 52:362–368. https://doi.org/10.1177/2168479018763591
Gokbuget N et al (2016a) International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. Haematologica 101:1524–1533. https://doi.org/10.3324/haematol.2016.144311
Gokbuget N et al (2016b) Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia. Blood Cancer J 6:e473. https://doi.org/10.1038/bcj.2016.84
Greenland S, Morgenstern H (2001) Confounding in health research. Annu Rev Public Health 22:189–212. https://doi.org/10.1146/annurev.publhealth.22.1.189
Kantarjian H et al (2017) Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 376:836–847. https://doi.org/10.1056/NEJMoa1609783
Lee SJ et al (2015) Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. Biol Blood Marrow Transplant 21:984–999. https://doi.org/10.1016/j.bbmt.2015.02.025
Li S, Molony JT, Cetin K, Wasser JS, Altomare I (2018) Rate of bleeding-related episodes in elderly patients with primary immune thrombocytopenia: a retrospective cohort study. Curr Med Res Opin 34:209–216. https://doi.org/10.1080/03007995.2017.1360852
Lim J et al (2018) Minimizing patient burden through the use of historical subject-level data in innovative confirmatory clinical trials: review of methods and opportunities. Ther Innov Regul Sci. https://doi.org/10.1177/2168479018778282
Pocock SJ (1976) The combination of randomized and historical controls in clinical trials. J Chronic Dis 29:175–188
Richardson PG et al (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487–2498. https://doi.org/10.1056/NEJMoa043445
USFDA USFaDA (2018) Real-world Evidence. https://www.fda.gov/scienceresearch/specialtopics/realworldevidence/default.htm. Accessed 15 Aug 2018
Funding Statement and Declarations of Conflicting Interest
CK, VC, and MK are employees and shareholders of Amgen Inc.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this entry
Cite this entry
Kim, C., Chia, V., Kelsh, M. (2021). Use of Historical Data in Design. In: Piantadosi, S., Meinert, C.L. (eds) Principles and Practice of Clinical Trials. Springer, Cham. https://doi.org/10.1007/978-3-319-52677-5_69-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-52677-5_69-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-52677-5
Online ISBN: 978-3-319-52677-5
eBook Packages: Springer Reference MathematicsReference Module Computer Science and Engineering